title: Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction.
abstract: IGF binding protein-1 (IGFBP-1) inhibits the mitogenic actions of the IGFs. Circulating IGFBP-1 is elevated in newborns and experimental animals with fetal growth restriction (FGR). To establish a causal relationship between high circulating IGFBP-1 and FGR, we have generated transgenic mice using the mouse alpha-fetoprotein gene promoter to target overexpression of human IGFBP-1 (hIGFBP-1) in the fetal liver. These transgenic mice (AFP-BP1) expressed hIGFBP-1 mainly in the fetal hepatocytes, starting at embryonic d 14.5 (E14.5), with lower levels in the gut. The expression peaked at 1 wk postnatally (plasma concentration, 474 +/- 34 ng/ml). At birth, AFP-BP1 pups were 18% smaller [weighed 1.34 +/- 0.02 g compared with 1.62 +/- 0.04 g for wild type (WT); P < 0.05], and they did not demonstrate any postnatal catch-up growth. The placentas of the AFP-BP1 mice were larger than WT from E16.5 onwards (150 +/- 12 for AFP-BP1 vs. 100 +/- 5 mg for WT at E16.5; P < 0.05). Thus, this model of FGR is associated with a larger placenta, but without postnatal catch-up growth. Overall, these data clearly demonstrate that high concentrations of circulating IGFBP-1 are sufficient to cause FGR.
authors.affiliation: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. watson@mshri.on.ca
authors.forename: Carole S
authors.initials: CS
authors.lastname: Watson
authors.forename: Peter
authors.initials: P
authors.lastname: Bialek
authors.forename: Makoto
authors.initials: M
authors.lastname: Anzo
authors.forename: Javad
authors.initials: J
authors.lastname: Khosravi
authors.forename: Siu-Pok
authors.initials: SP
authors.lastname: Yee
authors.forename: Victor K M
authors.initials: VK
authors.lastname: Han
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D015139:Blotting, Southern; D015153:Blotting, Western; D001835:Body Weight; D004247:DNA / Q000378:metabolism; D017931:DNA Primers / Q000737:chemistry; D018076:DNA, Complementary / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005317:Fetal Growth Retardation / Q000235:genetics*; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008024:Ligands; D008099:Liver / Q000196:embryology / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D008957:Models, Genetic; D015233:Models, Statistical; D010766:Phosphorylation; D010920:Placenta / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D012313:RNA / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014018:Tissue Distribution; D019076:Transgenes; D000509:alpha-Fetoproteins / Q000235:genetics
chemical_list: D017931:DNA Primers; D018076:DNA, Complementary; D018970:Insulin-Like Growth Factor Binding Protein 1; D008024:Ligands; D012333:RNA, Messenger; D000509:alpha-Fetoproteins; D012313:RNA; D007334:Insulin-Like Growth Factor I; D004247:DNA